An Update on Medical Management of Thyroid Eye Disease with Insights on Teprotumumab
Thyroid eye disease (TED) is a debilitating autoimmune condition. It occurs most commonly with the hyperthyroid state but can also be seen in euthyroid and hypothyroid states. Corticosteroids, steroid-sparing agents, and biologicals have been used, although none of them were Food and Drug Administra...
Saved in:
| Main Authors: | Smriti Dabas, Nishi Meghna Satish, Sangeeta Abrol |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2023-07-01
|
| Series: | Delhi Journal of Ophthalmology |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/DLJO.DLJO_131_23 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Teprotumumab and sensorineural hearing loss: a propensity score-matched retrospective cohort study
by: Maxim John Levy Barnett, et al.
Published: (2025-07-01) -
A randomized controlled trial on the effect of hydroxychloroquine in mild Graves’ orbitopathy (GO-HCQ): study protocol
by: Chia-Hung Lin, et al.
Published: (2025-08-01) -
SEARCH FOR TARGET TISSUE IN THE EYE ORBIT FOR AUTOIMMUNE AGGRESSION OF THYROID ANTIBODIES IN ENDOCRINE OPHTHALMOPATHY
by: V. G. Likhvantseva, et al.
Published: (2017-10-01) -
Efficacy and safety of various Intravenous Methylprednisolone regimens in Moderate to Severe Thyroid Eye Disease: A systematic review
by: Ankita Aishwarya, et al.
Published: (2025-08-01) -
A Case Report on the Thyroid and Eye Connection: A Deep Dive into Evaluation and Treatment Strategies
by: Iqra Mushtaq, et al.
Published: (2025-06-01)